VTRS

ViatrisC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

20%

Probability

Target price

$19.00

Analysis reference price unavailable

Analysis 2026-05-28 · RankAlpha Sentiment Codex

Most likely

Base case

55%

Probability

Target price

$15.80

Analysis reference price unavailable

Analysis 2026-05-28 · RankAlpha Sentiment Codex

B-

Bear case

25%

Probability

Target price

$12.50

Analysis reference price unavailable

Analysis 2026-05-28 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-05-28

AI commentary

Post-Q1 coverage was constructive but not exuberant: the company and Reuters both pointed to a beat and reaffirmed guidance, and the stock reacted positively around the print, but the packet does not show a strong post-earnings analyst revision wave. With the FDA decision on meloxicam still months away and no social context available, this remains a monitor-oriented setup rather than a high-conviction re-rate.

RankAlpha Sentiment Codex - 2026-05-28

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-07catalystQ1 2026 beat and guidance reaffirmationMedium impact

The May 7 Q1 package pointed to a stronger-than-expected first quarter, reaffirmed 2026 guidance, and highlighted Greater China strength, branded-drug demand, launch execution, and more than $2.5B of expected cash available for deployment in 2026. Reuters also reported the revenue/EPS beat and a positive immediate market reaction. [#10-Q-2026-05-07] [#PR-2026-05-07]

2026-12-27eventFast-acting meloxicam now has a Dec. 27, 2026 FDA clockMedium impact

Viatris said the FDA accepted the NDA for fast-acting meloxicam and assigned a PDUFA goal date of Dec. 27, 2026, creating a clear binary regulatory milestone for a value-added pipeline asset. [#PR-2026-05-18]

2026-12-31catalystJapan launch execution and capital-deployment capacity remain supportiveMedium impact

The Q1 release flagged additional product-launch progress, including Effexor in Japan, and reiterated that Viatris expects substantial 2026 cash generation for deployment, which gives the story a durable but modest operating tailwind beyond the core generics base. [#PR-2026-05-07] [#PR-2026-05-05]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-28 • Updated nightlySource: Internal modelMethodology